First brazilian consensus of advanced prostate cancer: recommendations for clinical practice

Autor: Diogo Assed Bastos, Marcus Vinicius Sadi, Volney Soares Lima, Fernando C. Maluf, Juliano Julio Cerci, George Coura Filho, Rodolfo Borges dos Reis, Oren Smaletz, Andre Deeke Sasse, Franz Campos, Leandro Casemiro Cezar, Gustavo F. Carvalhal, Evanius Garcia Wiermann, Ari Adamy, Igor Alexandre Protzner Morbeck, Daniel Herchenhorn, Fabio A.B. Schutz, Marcos Francisco Dall Oglio, Lucas Nogueira
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Zdroj: International braz j urol v.43 n.3 2017
International Braz J Urol
Sociedade Brasileira de Urologia (SBU)
instacron:SBU
International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology
International Brazilian Journal of Urology, Vol 43, Iss 3, Pp 407-415
International braz j urol, Volume: 43, Issue: 3, Pages: 407-415, Published: JUN 2017
Popis: Introduction Prostate cancer still represents a major cause of morbidity, and still about 20% of men with the disease are diagnosed or will progress to the advanced stage without the possibility of curative treatment. Despite the recent advances in scientific and technological knowledge and the availability of new therapies, there is still considerable heterogeneity in the therapeutic approaches for metastatic prostate cancer. Objectives This article presents a summary of the I Brazilian Consensus on Advanced Prostate Cancer, conducted by the Brazilian Society of Urology and Brazilian Society of Clinical Oncology. Materials and Methods Experts were selected by the medical societies involved. Forty issues regarding controversial issues in advanced disease were previously elaborated. The panel met for consensus, with a threshold established for 2/3 of the participants. Results and Conclusions The treatment of advanced prostate cancer is complex, due to the existence of a large number of therapies, with different response profiles and toxicities. The panel addressed recommendations on preferred choice of therapies, indicators that would justify their change, and indicated some strategies for better sequencing of treatment in order to maximize the potential for disease control with the available therapeutic arsenal. The lack of consensus on some topics clearly indicates the absence of strong evidence for some decisions.
Databáze: OpenAIRE